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Stem cell factor is essential to the migration and dif-
ferentiation of melanocytes during embryogenesis
based on the observation that mutations in either the
stem cell factor gene, or its ligand, KIT, result in
defects in coat pigmentation in mice. Stem cell fac-
tor is also required for the survival of melanocyte
precursors while they are migrating towards the skin.
Transforming growth factor b1 has been implicated
in the regulation of both cellular proliferation and
differentiation. NCC-melb4, an immortal cloned cell
line, was cloned from a mouse neural crest cell.
NCC-melb4 cells provide a model to study the speci-
®c stage of differentiation and proliferation of
melanocytes. They also express KIT as a melanoblast
marker. Using the NCC-melb4 cell line, we investig-
ated the effect of transforming growth factor b1 on
the differentiation and proliferation of immature
melanocyte precursors. Immunohistochemically,
NCC-melb4 cells showed transforming growth factor
b1 expression. The anti-transforming growth factor
b1 antibody inhibited the cell growth, and down-
regulated the KIT protein and mRNA expression.
To investigate further the activation of autocrine
transforming growth factor b1, NCC-melb4 cells
were incubated in nonexogenous transforming
growth factor b1 culture medium. KIT protein
decreased with anti-transforming growth factor b1
antibody concentration in a concentration-dependent
manner. We concluded that in NCC-melb4 cells,
transforming growth factor b1 promotes melanocyte
precursor proliferation in autocrine and/or paracrine
regulation. We further investigated the in¯uence of
transforming growth factor b1 in vitro using a neural
crest cell primary culture system from wild-type
mice. Anti-transforming growth factor b1 antibody
decreased the number of KIT positive neural crest
cell. In addition, the anti-transforming growth factor
b1 antibody supplied within the wild-type neural
crest explants abolished the growth of the neural
crest cell. These results indicate that transforming
growth factor b1 affect melanocyte precursor prolif-
eration and differentiation in the presence of stem
cell factor/KIT in an autocrine/paracrine manner.
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S
tem cell factor (SCF) induces its biologic effects via a
transmembrane tyrosine kinase type receptor named KIT,
which is expressed on melanocytes in the skin (Jiang et al,
2000). The proto-oncogene c-kit is a gene encoding a
tyrosine kinase receptor and has been mapped to the
dominant white spotting (W) locus (Chabot et al, 1988). SCF is the
ligand for KIT (c-kit protein) and has been mapped to the Steel (Sl)
locus (Zsebo et al, 1990). According to previous phenotype analysis
of W and Sl mice, it is clear that KIT and SCF play a crucial part in
the development of hematopoietic cells, germ cells, and melano-
cytes (Grabbe et al, 1994). SCF increases melanocyte proliferation,
differentiation, survival, chemotaxis, and secretion, as well as
accumulation in vivo (Nilsson et al, 1994; Costa et al, 1996;
Hartmann et al, 1997; Hermes et al 2001). Activation of the KIT
receptor in the presence of SCF indicates that SCF is essential to
melanocyte proliferation and differentiation during the early stages
(Scott et al, 1994; Hachiya et al 2001). The major role of SCF in
melanogenic phenomena was considered to be targeting KIT
receptor-bearing cells, melanoblasts or melanocytes, as evidenced
by the migration of melanoblasts from the neural crest toward hair
follicles via the epidermis (Hirobe, 1984). It has been observed that,
whereas mouse melanocyte precursors migrate from the neural crest
to the skin, they ®rst become KIT-positive, and differentiate into
tyrosinase positive, mature melanocytes.
Transforming growth factor (TGF)-b is one of a group of
cytokines that exert a spectrum of effects on various cell types and
cell stages (Roberts et al, 1985; Reiss and Sartorelli, 1987; Roberts
and Sporn, 1990). TGF-b1 is a multipotent growth factor with an
important role in tissue homeostasis. This growth factor regulates
cell proliferation, adhesion, migration, and differentiation, as well as
extracellular matrix deposition (Poole and Boyce, 1999). Within
human skin, TGF-b1 production has been reported in keratino-
cytes, melanocytes, ®broblasts, endothelial cells, macrophages, and
platelets (S®kakis et al, 1993; Wei-kang et al, 1993; Compton et al,
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1994; Rodeck et al, 1994; Frank et al, 1996). Some reports have
suggested that the effect of TGF-b1 depends on the degree of
differentiation of the target cell (Hoosein et al, 1989; Vollberg et al,
1991).
We have established an immortal cell population of neural crest
cells (NCC) from WB mice and designated them as NCC-S4.1
cells (Kawa et al, 2000). From these NCC-S4.1 cells, we cloned a
cell line named NCC-melb4 cells using a single-cell cloning
method. Previous studies have shown that NCC-melb4 cells are
immortal and stable in culture medium supplemented with SCF,
and they retain normal DNA ploidy and appeared to be immature
melanocytes (Ito et al in preparation). Thus, this cell line appears to
be ideal for studying factors that affect melanocyte development
and melanogenesis. Using the NCC-melb4 cell line, we investig-
ated the effect of TGF-b1 on the differentiation and proliferation of
immature melanocyte precursors.
In mouse embryos, melanoblasts, the precursors of skin
melanocytes, originate from NCC in the neural tube. Skin
melanocytes are derived from NCC that migrate into the dermis
and epidermis during embryogenesis (Rawles, 1947; Mayer, 1973).
SCF and KIT are required for the survival of melanocyte precursors
during their migration toward the skin (Nishikawa et al, 1991;
Murphy et al, 1992; Morrison-Graham and Weston, 1993; Ito et al,
1999). Previous ®ndings indicate that SCF/KIT signaling plays a
crucial part in the development of melanocytes from their
precursors in the embryonic NCC (Ito et al, 1999). The mouse
NCC primary culture system used in this study is an appropriate
experimental in vitro system for observing the differentiation of
melanocytes. Members of the TGF-b superfamily reportedly have
effects on NCC and their derivatives. For example, evidence
suggests that TGF-b1 regulates melanogenesis of NCC (Rogers et
al, 1992; Howard and Gershon, 1993; Varley et al, 1995). In this
study we examine the part TGF-b1 plays in melanocyte develop-
ment in mouse NCC in vitro.
MATERIALS AND METHODS
Mice C57BL/6 mice obtained from Japan SLC (Hamamatsu, Japan)
were used at day 9.5 postcoitum and were mated in our laboratory; the
midnight before the presence of a vaginal plug was termed E0.
Cells and culture conditions NCC-melb4 cells were established using
a single-cell cloning method from an immortal cell population (NCC-
S4.1) produced using NCC of WB mice (Kawa et al, 2000). The cells
were grown in a humidi®ed atmosphere of 5% CO2 and 95% air at
37°C in Eagle's minimum essential medium (MEM, IBL, Maebashi,
Japan) supplemented with 5% fetal bovine serum (FBS, Gibco, Grand
Island, NY) and 50 ng per ml of recombinant mouse SCF (Kirin
Brewery, Tokyo, Japan), unless indicated otherwise. Under these culture
conditions, the NCC-melb4 cells were KIT-positive, tyrosinase-negative
melanocyte precursors that remained at an immature undifferentiated
stage. Electron microscopic observations revealed that these cells
contained only stage I melanosomes with no advanced-stage
melanosomes.
To examine the possible contribution of the autocrine TGF-b loop,
we further cultured NCC-melb4 cells by changing the supplementation
in the culture medium from FBS + MEM + SCF to SCF + MEM. It
was assumed that the new medium did not include exogenous TGF-b1.
To better understand the role of endogenous TGF-b1 in NCC-melb4
cells, we investigated patterns of KIT protein production between the
two culture media.
NCC culture NCC culture was established as described by Ito and
Takeuchi (1984). Trunk regions posterior to the forelimb buds were
dissected from E9.5 embryos using tungsten needles. The trunks were
individually treated with 1% trypsin (Difco, Detroit, MI, 1:250) in
Tyrode's solution for 20 min at 4°C. Trypsinization was terminated by
washing with Tyrode's solution containing 10% FBS. The tissues were
gently pipetted using small-pore Pasteur pipettes to separate the neural
tubes from other components of the trunk. Eagle's MEM containing
15% FBS and 50 ng of soluble SCF per ml was used as the basic
medium. Neural tubes were explanted individually on to 12-well plates
(Falcon, Oxnard, CA) with 1 ml of medium per well. One-half of the
volume of culture medium in each well was changed every 3 d.
Proliferation assay NCC-melb4 cells were plated at 2000 cells per
well in 96-well plates. On the next day various concentrations of TGF-
b1 (Sigma Chemical Co, St Louis, MO) (0±20 ng per ml), anti-TGF-b1
antibody (Santa Cruz Biotechnology Inc., CA) (0±12.8 mg per ml) were
added to the culture medium (day 0). On days 0, 2, and 5, the cells
were incubated with Alamar Blue (Trek Diagnostic Systems, Wako Pure
Chemical Industries Ltd, Osaka, Japan) for 4 h at 37°C and the
¯uorescence was read on a Fluoroskan a microplate reader (Labsystems,
Helsinki, Finland). The antibody have been shown to be speci®c for the
different TGF-b isoforms as assessed by western blot analysis and
immunohistochemical staining (Frank et al, 1996; Gupta et al, 1996).
Immunohistochemical analysis of TGF-b1 and KIT expres-
sion NCC-melb4 cells were cultured on cover glasses on six-well
plates, and then immunostained. The cultures were ®xed in 95% ethanol
for 1.5 min (for monoclonal antibodies) or for 1 min (for polyclonal
antibodies) at 4°C and then were treated with normal goat serum (KPL,
Gaithersburg, MD) for 15 min at room temperature.
For the staining of TGF-b1, the cells were treated with anti-TGF-b1
polyclonal antibody (at 100 3 dilution) overnight at 4°C. Normal rabbit
serum (at 500 3 dilution) (DAKO, Carpinteria, CA) was used as a
negative control. The cells were then reacted with alkaline phosphatase-
labeled anti-rabbit IgG (at 100 3 dilution) (Southern Biotechnology
Associates, Birmingham, AL) for 1 h at room temperature.
For KIT staining, cells were treated with ACK2 (20 mg per ml) (a rat
anti-mouse KIT monoclonal antibody, which was generously supplied by
Dr Nishikawa, Kyoto University) or with normal rat IgG2b 20 mg per
ml (PharMingen, San Diego, CA) as a negative control, for 1 h at room
temperature. The cells were then reacted with alkaline phosphatase-
labeled anti-rat IgG (at 100 3 dilution) (Southern Biotechnology
Associates) for 1 h at room temperature.
Antibody localization was visualized using the New Fuchsin Substrate
System (DAKO, Carpinteria, CA) and a levamisole solution (Vector,
Burlingame, CA) as an inhibitor of internal alkaline phosphatase.
Western blotting NCC-melb4 cells were cultured in six-well plates
with MEM + SCF + FBS or MEM + SCF at a density of 5 3 104 cells
per well. TGF-b1 or anti-TGF-b1 antibody was added to the medium.
The dose-effect of the anti-TGF-b1 antibody was tested at the following
concentrations: 0.8, 1.6, 3.2, and 6.4 mg per ml in three wells each. Cell
extracts were collected by scraping and centrifugation. The cell pellets
were treated with a solubilization buffer containing 10 mM Tris±HCl,
pH 7.4, 150 mM NaCl, 10 mM MgCl2, and 1% Triton X-100, and the
cell extract was obtained following centrifugation 200 3 g at 1000 r.p.m.
for 10 min Aliquots of the sample were run on 10% sodium dodecyl
sulfate±polyacrylamide gel. After electrophoresis, proteins were
transferred on to a polyvinylidene di¯uoride membrane (Immobilon-p,
Millipore, Bedford, MA) and incubated with an anti-KIT monoclonal
antibody (ACK2; 20 mg per ml) overnight at room temperature. Alkaline
phosphatase-labeled anti-rat IgG (Southern Biotechnology Associates)
was used as a secondary antibody. Immunoreactive proteins were
detected using nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl
phosphate disodium salt (Sigma).
RNA extraction and reverse transcription±polymerase chain
reaction (reverse transcription±PCR) analysis Total RNA was
extracted from the cells using an RNA isolation kit (Qiagen, Hilden,
Germany) as described by the manufacturer. cDNA was prepared from
10 mg total RNA using MMLV Reverse Transcriptase (Gibco/BRL,
Gaithersburg, MD). The cDNA was ampli®ed using the PCR technique
(primer 1, 5¢-CGACTGCCCGTGAAGTGGA-3¢, primer 2, 5¢-GCC-
AGAAGGACGGGGTCGG-3¢) under the following conditions: 30
cycles each of denaturation at 94°C for 30 s, annealing at 60°C for
1 min and extension at 72°C for 2 min. PCR products were
electrophoresed on a 1.5% agarose gel. The gel was stained with
ethidium bromide and visualized under ultraviolet light in parallel with
DNA molecular weight markers. The predicted size of the KIT-PCR
products was 502 bp.
Statistical analysis Signi®cance differences were evaluated by Mann±
Whitney's U test. The level of signi®cance was set at p < 0.05 in all
cases.
RESULTS
Effects of TGF-b1 on the proliferation of NCC-melb4
cells Cell growth was assessed by Alamar Blue ¯uorescence assay
(Fig 1). NCC-melb4 cells grew best in the absence of TGF-b1 or
anti-TGF-b1 antibody. TGF-b1 adding was not suf®cient to
472 KAWAKAMI ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
induce maximum growth. When the antibody was added,
maximum growth was not achieved and some NCC-melb4 cells
were abolished. This growth was signi®cantly retarded after 5 d in
the presence of 0.08±20 ng per ml TGF-b1 or 3.2, 6.4, and 12.8 mg
per ml anti-TGF-b1 (p < 0.01). This effect was not signi®cantly
evident at anti-TGF-b1 antibody concentrations of 1.6 mg per ml or
less when NCC-melb4 was cultured in SCF for 2 and 5 d.
Immunohistochemical staining against anti-TGF-b1
antibody in NCC-melb4 cells Most NCC-melb4 cells were
strongly positive against the anti-TGF-b1 antibody compared with
controls (Fig 2). Immunohistochemical staining against the anti-
TGF-b1 antibody indicates the presence of TGF-b1 in NCC-
melb4 cells. Thus, NCC-melb4 cells appear to produce TGF-b1. It
was observed that some cells were also clearly TGF-b1 negative.
Effect of anti-TGF-b1 antibody on KIT expression in NCC-
melb4 cells To investigate whether SCF/KIT-induced
development is involved in the NCC-melb4 cells growth
inhibition by TGF-b1 or anti-TGF-b1 antibody, we examined
whether KIT expression in NCC-melb4 cells is inhibited by the
addition of TGF-b1 or anti-TGF-b1 antibody to the culture
medium. After treatment with TGF-b1 or anti-TGF-b1 antibody
for 1, 2, and 3 d, NCC-melb4 cell extracts were prepared and
analyzed by western blotting with monoclonal KIT antibody
(ACK2) as described in the Materials and Methods. As controls,
NCC-melb4 cells were incubated in a FBS + MEM + SCF-
supplemented medium. After 1, 2, or 3 d incubation with 0.08 ng
per ml extrinsic TGF-b1, expression of KIT protein was
commensurate with control (Fig 3A). After 3 d incubation with
3.2 mg anti-TGF-b1 antibody per ml, during ®rst 72 h expression
of the KIT protein decreased time-dependently (Fig 3B). We
further examined the concentration±effect relationship between the
anti-TGF-b1 antibody and KIT expression in cultured NCC-
melb4 cells. NCC-melb4 cells were extracted after 3 d incubation
with various concentrations (0.8, 1.6, 3.2, and 6.4 mg per ml) of
anti-TGF-b1 antibody (Fig 3C). KIT protein expression showed a
concentration-dependent decrease and completely disappeared at a
concentration of 6.4 mg per ml (Fig 3C, lane 5). To verify the role
of TGF-b1 on KIT expression, we tested the effect of an excess
amount of extrinsic TGF-b1 on the reduction of KIT protein
induced by anti-TGF-b1 antibody. As shown in Fig 3D, the
reduced KIT expression in the presence of anti-TGF-b1 antibody
recovered with the addition of TGF-b1.
Next, we examined the expression of the KIT transcript in
NCC-melb4 cells exposed for 3 d to 1.6 or 6.4 mg per ml anti-
Figure 1. Effects of anti-TGF-b1 antibody on the proliferation of
NCC-melb4 cells. NCC-melb4 cells were plated on 96-well plates at
2000 cells per well. On the next day, SCF, SCF + TGF-b1 or
SCF + anti-TGF-b1 antibody was added to the culture medium (day 1).
On days 1, 2, and 5 (a, b), cells were incubated with Alamar Blue for
4 h and the ¯uorescence was read on a Fluoroskan II microplate reader.
Greatest growth of NCC-melb4 cells was seen in the presence of SCF,
with lower rates seen in the presence of TGF-b1 or anti-TGF-b1
antibody. On day 5, NCC-melb4 cell growth was signi®cantly inhibited
by concentrations of 0.08±20 ng TGF-b1 per ml or 3.2, 6.4, and
12.8 mg per ml anti-TGF-b1 antibody compared with control wells
(**p < 0.01). Values represent mean 6 SD of eight determinations.
Figure 2. Immunohistochemical TGF-b1 staining of NCC-melb4
cells. Cells were cultured on cover glasses on six-well plates, and then
were immunohistochemically stained against TGF-b1 as described in the
Materials and Methods. The red cells in photomicrograph (a) represent
strongly TGF-b1-positive NCC-melb4 cells. Negative control: rabbit
serum (b).
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TGF-b1 antibody compared with normal controls (Fig 4). KIT
expression was maximally inhibited by 6.4 mg per ml of the anti-
TGF-b1 antibody at both the protein and mRNA levels. These
®ndings revealed a reduction in KIT expression by anti-TGF-b1
antibody at transcriptional level.
Effect of anti-TGF-b1 antibody on KIT expression in the
absence of extrinsic TGF-b1 Inhibition by the anti-TGF-b1
antibody raised the possibility of autocrine control in response to
SCF. To examine the effects of intrinsic TGF-b1, we changed the
culture medium from the one supplemented with MEM, SCF, and
FBS to the one supplemented without FBS including TGF-b1.
NCC-melb4 cells were then cultured in the presence or absence of
the anti-TGF-b1 antibody, and KIT protein expression detected by
western blot analysis. Following incubation, we found a
concentration-dependent decrease in KIT protein expression
(Fig 5). These results mirror those found in MEM + SCF +
FBS-supplemented medium, indicating that the concentration-
dependent decrease results are almost exclusively due to intrinsic
TGF-b1.
KIT expression in NCC in vitro primary cultures NCC
explants were ®xed at day 9 and subjected to immunohistochemical
staining against the anti-TGF-b1 antibody and anti-KIT antibody
(ACK2) (Fig 6). Almost all the NCC explants were positive for
TGF-b1 (Fig 6A). To determine the TGF-b1 dependency of
NCC via SCF/KIT signaling, we cultured the cells in either the
MEM + FBS + SCF-supplemented medium as described in the
Materials and Methods (Fig 6B) or medium with the anti-TGF-b1
antibody. The cells were then stained against the anti-KIT antibody
(ACK2) (Fig 6C, D). Nuclei were stained by nuclear fast red.
ACK2-positive cells were observed in the outer ring of
neuroepithelial sheets surrounding the neural tubes and peripheral
cells. Fewer KIT-positive cells were detected by light microscopy
in NCC incubated with the anti-TGF-b1 antibody (Fig 6C, D)
Figure 3. Western blot analysis of KIT on anti-TGF-b1 antibody
treated NCC-melb4 cells. NCC-melb4 cells were incubated for 1, 2,
and 3 d with TGF-b1 (0.08 ng per ml) (a) or anti-TGF-b1 neutralizing
antibody (3.2 mg per ml) (b). TGF-b1 did not change KIT expression in
NCC-melb4 cells as revealed by western blotting. (Lane 1: marker; lane
2: no TGF-b1, lane 3: 3 d; lane 4: 2 d; lane 5: 1 d.) The antibody
weakens KIT expression in NCC-melb4 cells as revealed by western
blotting. (Lane 1: marker; lane 2: no anti-TGF-b1 antibody, lane 3: 3 d;
lane 4: 2 d; lane 5: 1 d.) Cells were incubated in the absence of anti-
TGF-b1 antibody as controls, lane 2. KIT protein expression was lowest
in lane 3. We further analyzed the dose±response of anti-TGF-b1
antibody by western blot (c). Various concentrations (lane 2: 0.8 mg per
ml; lane 3: 1.6 mg per ml; lane 4: 3.2 mg per ml; lane 5: 6.4 mg per ml)
of anti-TGF-b1 antibody were added to the SCF medium. Cultures
were incubated for 3 d and the KIT protein was detected by western
blot. Note the reduced KIT expression at concentration of 1.6 and
3.2 mg per ml (lanes 3 and 4), and this was reduced to no expression at
6.4 mg per ml (lane 5). TGF-b1 (50 ng per ml) was added to SCF
medium in the presence of anti-TGF-b1 antibody (1.6 mg per ml; lane 4)
(d). Cultures were incubated for 3 d and KIT protein was detected by
western blot. Note the recovered KIT expression compared with anti-
TGF-b1 antibody (lanes 3 and 4). [Lane 2: positive control (neither
TGF-b1 nor anti-TGF-b1)].
Figure 4. Effect on mRNA expression of anti-TGF-b1 antibody
compared with b-actin. PCR products were analyzed by 1.5%
agarose-gel electrophoresis and ethidium-bromide staining. [Lane 1:
marker; lane 2: no anti-TGF-b1 antibody; lane 3: 1.6 mg anti-TGF-b1
per ml; lane 4: 6.4 mg anti-TGF-b1 per ml; lane 5: negative control
(omission of template cDNA).] A KIT-speci®c 502 bp fragment, the
predicted size, was evident in lanes 2±4. As quantitative controls, b-actin
ampli®cation products are shown in the bottom panel. KIT mRNA
expression decreased with anti-TGF-b1 antibody concentration in a
concentration-dependent manner.
Figure 5. Western blot analysis of KIT expression in NCC-melb4
cells incubated FBS-free medium NCC-melb4 cells were
incubated in a culture medium free of FBS and exogenous TGF-
b1, and supplemented with MEM and SCF. Various concentrations
of anti-TGF-b1 antibody (lane 2: 0.8 mg per ml; lane 3: 1.6 mg per ml;
lane 4: 6.4 mg per ml) were added to the medium.
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than in MEM + FBS + SCF-supplemented medium (Fig 6B).
KIT-positive cells did not differ morphologically between those
incubated in MEM + FBS + SCF-supplemented medium and the
medium with the anti-TGF-b1 antibody. This suggests that the
anti-TGF-b1 antibody in¯uences the degree of KIT expression in
NCC in vitro.
Effect of high anti-TGF-b1 antibody on NCC in vitro On
day 3, NCC explants were cultured in MEM + FBS + SCF-
supplemented medium with various concentrations of the anti-
TGF-b1 antibody (ACK2; 0, 1.6, 6.4 mg per ml), following by
light microscopic observation (Fig 7). The addition of the anti-
TGF-b1 antibody resulted in a noticeable decrease in the number
of NCC. Fewer NCC explants were seen with 1.6 mg anti-TGF-
b1 antibody per ml at day 6 (Fig 7B) and became undetectable in
the neuroepithelial sheets at day 12 (Fig 7E). At a concentration of
6.4 mg per ml, NCC explants did not survive and were completely
abolished by day 5 (Fig 7C).
DISCUSSION
TGF-b denotes a family of structurally related polypeptide growth
factors that control proliferation and differentiation of many cell
types. Members of the TGF-b superfamily have been associated
with phenomena as diverse as embryonal development, wound
healing, differentiation, and immune response to a variety of
stimuli. Dorsalin-1, which is a novel member of the TGF-b
superfamily, appears to regulate cell differentiation within the
neural tube. This factor is expressed selectively in the dorsal neural
tube and its pattern of expression is restricted by early signals from
the notochord (Basler et al, 1993). Recent data obtained in avian
systems indicate that the bone morphogenic protein, which belongs
to the TGF, superfamily, promotes expression of catecholaminergic
properties by NCC (Varley et al, 1995; Shah et al, 1996). Control of
cellular proliferation by TGF-b, is bidirectional; growth of
epithelial and hemopoietic cells is frequently inhibited, whereas
growth of mesenchymal cells is often stimulated by TGF-b
activities. The homeostatic role of TGF-b in the normal organism
is highlighted by the recent ®nding that targeted disruption of the
mouse TGF-b1 gene results in excessive in¯ammatory reactions
leading to organ failure and death (Rodeck et al, 1994; Shull et al,
1992; Kulkarni et al, 1993).
Previous results indicate that melanocytes typically exist in an
environment with a high level of TGF-b. Hu et al (1998)
concluded that TGF-b may be an important, if not the exclusive,
growth inhibitory factor of melanocytes in vivo, and therefore plays
an important part in maintaining the relatively quiescent state of
melanocytes in vivo. Several studies have suggested that loss of
response to the growth inhibiting effects of TGF-b or loss of ability
to produce TGF-b or activate endogenous TGF-b in transformed
cells may interfere with the normal growth-regulatory mechanism,
leading to uncontrolled growth of transformed cells (Roberts et al,
1985; Arteaga et al, 1990; Miller et al, 1990). Furthermore, TGF-b
has been implicated as a factor in the self-renewal of NCC (Shah
et al, 1996).
Although the biologic activities of TGF-b1, TGF-b2, and TGF-
b3 are similar in most cell types, differential expressions of these
isoforms play distinct regulatory roles in a variety of developmental,
physiologic, and pathologic situations. TGF-b1 is a potent growth
inhibitory factor and a modulator of differentiation in several cell
types. This process is promoted in chondroblasts, osteoblasts, and
some epithelial cells (MassagueÂ, 1990). Despite the apparent
relationship between TGF-b1 and cell differentiation, there have
been few studies on the relationship between the degree of cellular
differentiation and TGF-b1 action. When applied to trunk NCC
Figure 6. Immunohistochemical TGF-b1 and KIT staining of NCC. NCC explants were cultured on six-well plates, and then were
immunohistochemically stained as described in the Materials and Methods. (a) TGF-b1 staining; (b±d) KIT staining. Red cells in the photomicrograph (a)
represent strongly TGF-b1-positive NCC. Cultured from day 3 to day 9 in the presence of anti-TGF-b1 antibody (c: 0.4 mg per ml; d: 0.8 mg per ml),
the number of KIT positive cells decreased in a concentration-dependent manner compared with controls (b).
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in vitro, TGF-b1 itself promotes migration from the premigratory
crest (Delannet and Duband, 1992). In our study, a growth curve
drawn for Alamar Blue-stained cells showed that NCC-melb4 cells,
melanocyte precursors, were dependent on TGF-b1. Furthermore,
immunohistochemical staining revealed the presence of TGF-b1 in
NCC-melb4 cells. These ®ndings suggest that TGF-b1 is involved
in melanocyte proliferation and differentiation.
KIT is a receptor tyrosine kinase, which is expressed in the
melanocyte precursors that migrate toward the skin. At some time
during the process of differentiation, mouse melanocyte precursors
are KIT-positive, and their binding to the ligand SCF results in a
signal that is required for their survival, proliferation, and
differentiation into the next stage (Grabbe et al, 1994; Ono et al,
1998). Hachiya et al (2001) suggested that SCF/KIT signaling is
critically involved in the biologic mechanism of melanogenesis. We
examined the effect of TGF-b1 combined with SCF/KIT on the
growth and differentiation of melanocyte precursors. Western
blotting revealed a reduction in KIT protein levels within the
NCC-melb4 cells that seemed to be concentration dependent with
respect to the anti-TGF-b1 antibody. This same pattern was also
evident at the mRNA level by reverse transcription±PCR.
Moreover, the addition of extrinsic TGF-b1 neutralized the
inhibitory effect of anti-TGF-b1 antibody on KIT protein
expression. These results suggest that TGF-b1 combined with
Figure 7. NCC growth in the presence of anti-TGF-b1 antibody. NCC explants were cultured in growth medium (a: day 6; d: day 12),
containing either 1.6 mg per ml (b: day 6; e: day 12) or 6.4 mg per ml (c) exogenous anti-TGF-b1 antibody from day 3. Development was adversely
affected in the presence of the anti-TGF-b1 neutralizing antibody (b, c, e), showing no formation of the neuroepithelial sheet that surrounds the neural
tube (b, d). At a concentration of 6.4 mg per ml, NCC could not survive, leaving only remnants of the neural tube by day 5 (c). In wild-type neural
crest explants, cell growth was also inhibited by adding anti-TGF-b1 antibody.
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SCF/KIT signaling may play a contributory role as an active factor
in the induction of various functions in NCC-melb4 cells. The
involvement of other TGF-b, such as TGF-b2 and TGF-b3, is not
clear at present and needs to be investigated further.
An autocrine cytokine loop may be initiated in vivo by exposure
to certain cytokines and may continue to operate under cell culture
conditions (Kawakami et al, 1998). Several groups have examined
expression of the SCF/KIT system in tumor tissues and found that
it may serve an autocrine function (Bellone et al, 1997). TGF-b
family members frequently exert multiple autocrine and paracrine
efforts that can result in cellular proliferation and differentiation.
TGF-b1 is another candidate for such induction, either acting
independently or in conjunction with the SCF/KIT system.
Immunohistochemical staining indicated most NCC-melb4 cells
were strongly positive against anti-TGF-b1 antibody. On the other
hand, staining also revealed some cells were clearly TGF-b1
negative. This means that the population of NCC-melb4 cells is
heterogeneous according to TGF-b1 expression, and TGF-b1
released from a TGF-b1-positive subpopulation may in¯uence
TGF-b1-negative cells in a paracrine manner. These ®ndings raise
the question of whether TGF-b1 represents a positive autocrine/
paracrine growth regulator in SCF/KIT signaling. To understand
better the potential autocrine/paracrine role of NCC-melb4-
derived TGF-b1, we investigated further patterns of KIT protein
production in non-TGF-b1 medium compared with the standard
medium. Extrinsic TGF-b1 did not appear to in¯uence signi®c-
antly the KIT protein expression pattern according to western
blotting, indicating that intrinsic TGF-b1 in NCC-melb4 cells is
the primary in¯uence on KIT expression. These results indicate
that TGF-b1 regulates the melanogenesis mechanism in NCC-
melb4 cells in an autocrine/paracrine fashion via SCF/KIT
signaling.
It has been reported that TGF-b1 affects melanogenesis of NCC
by regulating patterns of cell dispersal (Shah et al, 1996). We
detected the presence of TGF-b1 in NCC in vitro by immuno-
histochemical staining. The number of KIT immunohistochemical
positive cells decreased in the presence of the anti-TGF-b1
antibody in a concentration-dependent manner. TGF-b1 has
been implicated in the survival and proliferation of NCC in vitro
via SCF/KIT signaling. To examine further the TGF-b1 depend-
ency of NCC in vitro, we explanted and cultured individual neural
tubes in a medium with the anti-TGF-b1 antibody and compared
them with those in the basic medium. The normal development of
derivatives of the crest appears to depend on the action of TGF-b1,
as demonstrated by their abnormal development in NCC embryos
cultured with the anti-TGF-b1 antibody. This could permit direct
effects of the factor or interactions with other factors produced by
the cultures themselves. TGF-b1 has the ability to elicit NCC
differentiation into melanocytes in the presence of exogenous SCF;
however, it is not as effective as SCF as evidenced by more
advanced development of various melanoblasts in the wild-type
neural crest explants cultured with SCF.
In summary, we detected that NCC-melb4 cells and NCC
in vitro secrete TGF-b1. Furthermore, the anti-TGF-b1 antibody
inhibits KIT expression by autocrine/paracrine regulation. These
observations led us to hypothesize that intrinsic TGF-b1 combined
with SCF/KIT plays an important part in vertebrate neural
development. The present ®ndings provide important clues
towards understanding the roles and working mechanisms of
TGF-b1 in melanocyte development and melanogenesis.
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